<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" id="bjh15459-fig-0001" orientation="portrait" position="float">
 <label>Figure 1</label>
 <caption>
  <p>
   <styled-content style="fixed-case">CONSORT</styled-content> diagrams. For the intensive pathway (A), non‚Äêintensive pathway (B) and the maintenance phase (C). 
   <styled-content style="fixed-case">CTD</styled-content>, cyclophosphamide, thalidomide and dexamethasone; 
   <styled-content style="fixed-case">CTD</styled-content>a, attenuated cyclophosphamide, thalidomide and dexamethasone; 
   <styled-content style="fixed-case">CVAD</styled-content>, cyclophosphamide, vincristine, doxorubicin and dexamethasone; 
   <styled-content style="fixed-case">ITT</styled-content>, intention to treat; MP, melphalan and prednisolone; QoL, quality of life.
  </p>
 </caption>
 <graphic id="nlm-graphic-1" xlink:href="BJH-182-816-g001" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
